Reactivation of herpes simplex virus type 1 (HSV-1) has been described in critically ill patients with coronavirus disease 2019 (COVID-19) pneumonia. In the present two-center retrospective experience, we primarily aimed to assess the cumulative risk of HSV-1 reactivation detected on bronchoalveolar fluid (BALF) samples in invasively ventilated COVID-19 patients with worsening respiratory function. The secondary objectives were the identification of predictors for HSV-1 reactivation and the assessment of its possible prognostic impact. Overall, 41 patients met the study inclusion criteria, and 12/41 patients developed HSV-1 reactivation (29%). No independent predictors of HSV-1 reactivation were identified in the present study. No association was found between HSV-1 reactivation and mortality. Eleven out of 12 patients with HSV-1 reactivation received antiviral therapy with intravenous acyclovir. In conclusion, HSV-1 reactivation is frequently detected in intubated patients with COVID-19. An antiviral treatment in COVID-19 patients with HSV-1 reactivation and worsening respiratory function might be considered.
【저자키워드】 COVID-19, SARS-CoV-2, intensive care, Reactivation, HSV-1, BALF, herpes simplex virus, 【초록키워드】 coronavirus disease, antiviral therapy, Mortality, Pneumonia, Respiratory function, Antiviral treatment, virus, Patient, predictor, prognostic, association, retrospective, COVID-19 patient, criteria, intravenous, Critically ill patient, Ventilated, worsening, study inclusion, herpes simplex, bronchoalveolar, cumulative risk, described, independent predictor, intubated patient, with COVID-19, 【제목키워드】 center, Italian, lavage, Result, Sample, Type, Herpe, Ill, Mechanical,